Osteoprotegeryna jako marker choroby niedokrwiennej serca u osób z cukrzycą Artykuł przeglądowy

##plugins.themes.bootstrap3.article.main##

Aleksandra Rumianowska
Beata Mrozikiewicz-Rakowska
Waldemar Karnafel

Abstrakt

W ostatnich latach wiele badań dotyczących patogenezy procesu miażdżycowego skupiło się na osteoprotegerynie – cytokinie, która pierwotnie była uważana za czynnik regulujący procesy przebudowy kostnej. W świetle najnowszych badań wydaje się, że osteoprotegeryna i układ cytokin OPG/RANKL/RANK zaangażowane są w proces kalcyfikacji naczyń, który leży u podłoża wielu powikłań cukrzycy. Podwyższone stężenie osteoprotegeryny uważane jest za czynnik ryzyka chorób sercowo-naczyniowych. W niniejszej pracy prezentujemy wyniki badań dotyczących udziału osteoprotegeryny w patogenezie miażdżycy naczyń wieńcowych u osób chorych na cukrzycę. Przedstawiamy także potencjalne korzyści kliniczne wynikające z oznaczania stężenia OPG w szacowaniu ryzyka wystąpienia incydentów sercowo-naczyniowych.

Pobrania

Dane pobrania nie są jeszcze dostepne

##plugins.themes.bootstrap3.article.details##

Jak cytować
Rumianowska , A., Mrozikiewicz-Rakowska , B., & Karnafel , W. (2014). Osteoprotegeryna jako marker choroby niedokrwiennej serca u osób z cukrzycą . Kardiologia W Praktyce, 8(1), 30-35. Pobrano z https://journalsmededu.pl/index.php/kwp/article/view/1543
Dział
Artykuły

Bibliografia

1. Simonet W.S., Lacey D.L., Dunstan C.R. et al.: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-319.
2. Lacey D.L., Timms E., Tan H.L. et al.: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-176.
3. Yun T.J., Chaudhary P.M., Shu G.L. et al.: OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J. Immunol. 1998; 161: 6113-6121.
4. Tan K.B., Harrop J., Reddy M. et al.: Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and nonhematopoietic cells. Gene 1997; 204: 35-46.
5. Knudsen S.T., Foss C., Poulsen P.L. et al.: Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur. J. Endocrinol. 2003; 149: 39-42.
6. Hakeda Y., Kobayashi Y., Yamaguchi K. et al.: Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone resorbing activity of isolated mature osteoclasts. Biochem. Biophys. Res. Commun. 1998; 251: 796-801.
7. Akatsu T., Murakami T., Nishikawa M. et al.: Osteoclastogenesis-inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast. Biochem. Biophys. Res. Commun. 1998; 250: 229-234.
8. Emery J.G., McDonnell P., Burke M.B. et al.: Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 1998; 273: 14363-14367.
9. Hofbauer L.C., Shui C., Riggs B.L. et al.: Effects of immunosuppressants on receptor activator of NF-κB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem. Biophys. Res. Commun. 2001; 280: 334-339.
10. Bucay N., Sarosi I., Dunstan C.R. et al.: Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998; 12(9): 1260-1268.
11. Schoppet M., Al-Fakhri N., Franke F.E. et al.: Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Monckeberg’s sclerosis and atherosclerosis. J. Clin. Endocrinol. Metab. 2004; 89: 4104-4112.
12. Niskanen L., Siitonen O., Suhonen M. et al.: Medial artery calcification predicts cardiovascular mortality in patients with NIDDM. Diabetes Care 1994; 17: 1252-1256.
13. Lehto S., Niskanen L., Suhonen M. et al.: Medial artery calcification. A neglected harbinger of cardiovascular calcificationsin non insulin dependent diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 1996; 16: 978-983.
14. Jorsal A., Tarnow L., Flyvbjerg A. et al.: Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetologia 2008; 51: 2100-2107.
15. Browner W., Lui L., Cummings S.: Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures and mortality in elderly women. J. Clin. Endocrinol. Metab. 2001; 86: 631-637.
16. Hughes A.E., Ralston S.H., Marken J. et al.: Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat. Genet. 2000; 24: 45-48.
17. Olesen P., Nguyen K., Wogensen L. et al.: Calcification of human vascular smooth muscle cells: associationswith osteoprotegerin expression and acceleration by high-dose insulin. Am. J. Physiol. Heart Circ. Physiol. 2007; 292: H1058-H1064.
18. Dhore C.R., Cleutjens J.P., Lutgens E. et al.: Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. 2001; 21: 1998-2003.
19. Olesen P., Ledet T., Rassmusen L.M.: Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular sooth muscle cells by insulin and TNF-alpha. Diabetologia 2005; 48: 561-568.
20. Vaccarezza M., Bortul R., Fadda R. et al.: Increased OPG expression and impaired OPG/TRAIL ratio in the aorta of diabetic rats. Med. Chem. 2007; 4: 387-391.
21. Heinonen S.E., Leppänen P., Kholová I. et al.: Increased atherosclerotic lesion calcification in a novel mouse model combining insulin resistance, hyperglycemia and hypercholesterolemia. Circ. Res. 2007; 101: 1058-1067.
22. Hofbauer L.C., Schoppet M.: Osteoprotegerin: a link between osteoporosis and arterial calcification? Lancet 2001; 358: 257-259.
23. Rasmussen L.M., Ledet T.: Osteoprotegerin and diabetic macroangiopathy. Horm. Metab. Res. 2005; 37(supl. 1): 90-94.
24. Jono S., Ikari Y., Shioi A. et al.: Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002; 106: 1192-1194.
25. Libby P., Ridker P.M., Maseri A.: Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.
26. Zhang J., Fu M., Myles D. et al.: PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett. 2002; 521: 180-184.
27. Fu M., Zhang J., Lin Y. et al.: Activation of peroxisome proliferator-activated receptor – inhibits osteoprotegerin gene expression in human aortic smooth muscle cells. Biochem. Biophys. Res. Commun. 2002; 294: 597-601.
28. Shin J., Shin Y., Chung C.: Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. Diabetes Care 2006; 29: 1664-1666.
29. Xiang G.D., Sun H.L., Zhao L.S. et al.: Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients. Diabetes Res. Clin. Pract. 2007; 76: 199-206.
30. Xiang G.D., Xu L., Zhao L.S. et al.: The relationship between plasma osteoprotegerin and endotheliumdependent arterial dilation in type 2 diabetes. Diabetes 2006; 55: 2126-2131.
31. Malyankar U.M., Scatena M., Suchland K.L. et al.: Osteoprotegerin is an αvβ3-induced NF-κB–dependent survival factor for endothelial cells. J. Biol. Chem. 2000; 275: 20959-20962.
32. Celczynska-Bajew L., Horst-Sikorska W., Bychowiec B. et al.: The effects of osteoprotegerin (OPG) gene polymorphism in patients with ischaemic heart disease on the morphology of coronary arteries and bone mineral density. Kardiologia Polska 2011; 69 (6): 573-578.
33. Clancy P., Oliver L., Jayalath R. et al.: Assessment of a serum assay for quantification of abdominal aortic calcification. Arterioscler. Thromb. Vasc. Biol. 2006; 26: 2574-2576.
34. Kiechl S., Schett G., Wenning G. et al.: Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004; 109: 2175-2180.
35. Schoppet M., Sattler M., Schaefer J. et al.: Increased osteoprotegerin serum levels in men with oronary artery disease. J. Clin. Endocrinol. Metab. 2003; 88: 1024-1028.
36. Galluzzi F., Stagi S., Salti R. et al.: Osteoprotegerin serum levels in children with type 1 diabetes: a potential modulating role in bone status. Eur. J. Endocrinol. 2005; 153: 879-885.
37. Nabipour I., Kalantarhormozi M., Larijani B. et al.: Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women. Metabolism 2010; 59: 742-747.
38. Semb A.G., Ueland T., Aukrust P. et al.: Osteoprotegerin and Soluble Receptor Activator of Nuclear Factor-κB Ligand and Risk for Coronary Events A Nested Case – Control Approach in the Prospective EPIC-Norfolk Population Study 1993–2003. Arterioscler. Thromb. Vasc. Biol. 2009; 29: 975-980.
39. Anand D.V., Lahiri A., Lim E. et al.: The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J. Am. Coll. Cardiol. 2006; 47: 1850-1857.
40. Vik A., Mathiesen E.B., Brox J. et al.: Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: \The Tromso Study. Journal of Thrombosis and Haemostasis 2011; 9(4): 638-644.
41. Reinhard H., Lajer M., Gall M.A. et al.: Osteoprotegerin and mortality in type 2 diabetic patients. Diabetes Care 2010; 33(12): 2561-2566.
42. Secchiero P., Corallini F., Beltrami A.P. et al.: An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. Atherosclerosis 2010; 210: 274-277.
43. Rasmussen L.M., Tarnow L., Hansen T.K. et al.: Plasma osteoprotegerin is associated with glycemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur. J. Endocrinol. 2006; 154: 75-81.
44. Viereck V., Gründker C., Blaschke S. et al.: Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts. J. Cell. Biochem. 2005; 96(6): 1244-1253.
45. Price P.A., June H.H., Buckley J.R. et al.: Osteoprotegerin inhibits artery calcification induced by warfarin and vitamin D. Arterioscler. Thromb. Vasc. Biol. 2001; 21: 1610-1616.